Rearrangements of the neuregulin (NRG1) gene have been implicated in breast carcinoma oncogenesis. To determine the frequency and clinical significance of NRG1 aberrations in clinical breast tumors, a breast cancer tissue microarray was screened for NRG1 aberrations by fluorescent in situ hybridization (FISH) using a two-color split-apart probe combination flanking the NRG1 gene. Rearrangements of NRG1 were identified in 17/382 cases by FISH, and bacterial artificial chromosome array comparative genomic hybridization was applied to five of these cases to further map the chromosome 8p abnormalities. In all five cases, there was a novel amplicon centromeric to NRG1 with a minimum common region of amplification encompassing two genes, SPFH2 and FLJ14299. Subsequent FISH analysis for the novel amplicon revealed that it was present in 63/262 cases. Abnormalities of NRG1 did not correlate with patient outcome, but the novel amplicon was associated with poor prognosis in univariate analysis, and in multivariate analysis was of prognostic significance independent of nodal status, tumor grade, estrogen receptor status, and human epidermal growth factor receptor (HER)2 overexpression. Of the two genes in the novel amplicon, expression of SPFH2 correlated most significantly with amplification. This amplicon may emerge as a result of breakpoints and chromosomal rearrangements within the NRG1 locus.
Introduction
Chromosomal translocations are a common feature of sarcoma, leukemia and lymphoma, but little is known about their role in common epithelial malignancies. A translocation t(12;15) leading to ETV6-NTRK3 gene fusion is a specific event in secretory carcinoma, a rare form of breast cancer (Tognon et al., 2002; Makretsov et al., 2004a) . This was the first report of a recurrent and subtype-specific translocation in breast cancer and raises the possibility that translocations could define other clinically relevant subtypes of breast cancer. The short arm of chromosome 8 is a site of frequent chromosomal abnormalities in breast cancers and breast cancer cell lines, including gene amplification events and translocations. In breast cancers, the NRG1 and FGFR1 genes have frequently been involved in cytogenetic abnormalities of 8p11-12 (Bernardino et al., 1998; Liu et al., 1999; Ugolini et al., 1999; Adelaide et al., 2000 Adelaide et al., , 2003 Birnbaum et al., 2003; Ray et al., 2004) .
NRG1 codes for at least 15 different isoforms through alternative splicing, including four heregulin (HRG) isoforms, which are ligands for members of the ERBB/ human epidermal growth factor receptor (HER) family Falls, 2003) . These HRG isoforms start transcription at exon 2, completely bypassing exon 1, which is located 955 kb away at the telomeric end of the gene. Binding of HRG ligands to HER3 facilitates heterodimerization of HER3 with HER2 and stimulates a signaling cascade that effects proliferation, survival, and differentiation (as reviewed by Yarden and Sliwkowski, 2001 ). HER2 is overexpressed in 15-25% of ductal breast cancers and this overexpression correlates with poor prognosis (Yarden and Sliwkowski, 2001 ). HER1 and HER3 overexpression are also associated with poor prognosis in breast cancer (Wiseman et al., 2005) . Furthermore, HRG has been shown to promote tumor growth in vivo and induce metastasis (Atlas et al., 2003) . The known oncogenic role of HRG has provided the rationale for considering NRG1 as a potential target of 8p12 rearrangements in breast carcinoma.
In breast cancer cell lines, there have been seven breakpoints described within or around NRG1, and a translocation with DOC4 located on chromosome 11 has been described in the MDA-MB-175 cell line (Liu et al., 1999; Wang et al., 1999; Adelaide et al., 2003) . This translocation gives rise to a secreted fusion protein (Liu et al., 1999; Wang et al., 1999; Adelaide et al., 2003) that has been demonstrated to have an autocrine growth effect (Schaefer et al., 1997) . Huang et al. (2004) identified NRG1 breaks in 6% of breast cancers. The cases with NRG1 breaks tended to be HER2 negative and estrogen receptor (ER) positive. They also reported a significant correlation with FGFR1 overexpression. They hypothesized that these breakpoints result in translocation events that lead to breast cancer development through abnormal expression of the 3 0 -end of NRG1. They have shown translocation events in four breast cancer cell lines (ZR-75-1, HCC1937, UACC-812, and MDA-MB-175) and demonstrated gain of the 8p11-12 region in three cell lines (SUM-52, ZR-75-1, and MDA-MB-134) . It is, however, possible that chromosomal rearrangements within intron 1 of the NRG1 gene do not represent genespecific translocations and that these events may be part of some other cytogenetic process. Factors that make the gene-specific hypothesis less likely include: (1) the lack of common fusion partners or a clearly oncogenic fusion transcript, (2) the lack of a consistent association between NRG1 breaks and NRG1 mRNA or protein levels, (3) the lack of any correlation between NRG1 abnormalities and expression of the epidermal growth factor receptors (HER1, HER2, HER3, and HER4), and (4) the lack of strong and specific clinical associations with NRG1 rearrangements, as has been seen for the t(12;15) translocation and secretory carcinomas.
To determine the frequency and further delineate the clinical significance of chromosomal rearrangements within and surrounding the NRG1 gene, we analysed 438 clinically annotated breast cancers using fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC). In five cases with NRG1 rearrangements, bacterial artificial chromosome (BAC) array comparative genomic hybridization (CGH) was performed. A second series of cases with matched frozen tissue samples was used to determine the association between gene copy number and expression levels of specific genes identified as being amplified through BAC array CGH.
Results

Three distinct types of NRG1 aberrations
A three-color FISH assay consisting of a centromere 8 probe (aqua) together with probes flanking the 5 0 -end (green) and the 3 0 -end (orange) of the NRG1 gene was performed on the tissue microarray (TMA) series of 438 clinically annotated breast cancers. A total of 358 cases produced FISH signals of sufficient intensity and clarity for analysis (81.7% of all cases). The remaining cases were not assessable due to poor FISH hybridization, insufficient numbers of tumor cells, tissue loss, or tissue over/underdigestion. In all, 17 (4.7%) of the cases showed abnormal NRG1 signals, excluding aneuploidy. Three distinct types of abnormalities were seen: (A) low copy number of the 3 0 (centromeric)-end of the gene with respect to the 5 0 (telomeric)-end of the gene (two cases), (B) low copy number of the 5 0 -end of the gene with respect to the 3 0 -end of the gene (12 cases), and (C) amplification of both ends of the gene (three cases) (Figure 1a) . The two cases with type A NRG1 aberrations showed either loss of the 3 0 -end of NRG1 (case number 152) or gain of the 5 0 -end of NRG1 (case number 77) (Figure 1b) . Type B aberrations were the most frequently observed, with loss of the 5 0 signal being present in 11 cases, two of which also had 3 0 amplification events (cases 87 and 179). The remaining nine cases with type B abnormalities had increased copy number of the 3 0 -end of NRG1 due to loss of the 5 0 -end of the gene without 3 0 amplification. A single case (case 286) with type B abnormality showed amplification of the 3 0 -end of NRG1 only ( Figure 1c ). Three cases: 285, 303, and 382 showed type C abnormalities (Figure 1d ), and this is most likely indicative of whole gene amplification.
A second set of FISH probes was applied to the 17 cases demonstrating NRG1 aberrations, one covering exon 1 and the other covering exons 2-17 of the gene. Exon 2 is located 955 kb away from exon 1 and specifically represents the start of the HRG coding region . This specific (internal) probe set showed fewer abnormalities than were seen with the flanking (external) probes. For example, both cases showing type A abnormalities (loss of the 3 0 -end) no longer showed a difference in copy number between the 5 0 -and the 3 0 -end of NRG1. The different locations of both specific and flanking probe sets are demonstrated in Figure 2a and complete results are listed in Figure 1a .
HRG correlates significantly with tumor grade, p53, and HER1
There was no statistically significant correlation between NGR1 aberrations, either individually or taken as a group, and the biomarkers, ER, p53, Ki67, HER1, HER2, or HER3, nor with tumor grade, nodal status, or histological subtype. NRG1 abnormalities were not associated with poor survival.
There was no significant correlation between HRG IHC and NRG1 aberrations. HRG immunostaining was seen in 60% of the tumors, with 19% demonstrating strong immunostaining. HRG immunostaining intensity correlated positively with tumor grade (P ¼ 0.007), p53 (P ¼ 0.001), and Ki67 (P ¼ 0.01), and correlated negatively with ER (P ¼ 0.016) and PR (P ¼ 0.017). A positive and statistically significant correlation between HRG and HER1 (P ¼ 0.015) was observed but not with the other members of the epidermal growth factor receptor family, HER2 (P ¼ 0.5), HER3 (P ¼ 0.4), and HER4 (P ¼ 0.2). All five cases show significant levels of amplification by array CGH and validated by FISH for an amplicon centromeric to the NRG1 gene and telomeric to FGFR1, while FGFR1 shows gain of copy number in only two of five cases by array CGH (Figure 2b ) and gain in four of five cases by FISH (Figure 2c ). For all five cases, the minimal common region of amplification within the novel amplicon contains two Refseq annotated genes, SPFH2 and FLJ14299. SPFH2 was formally known as C8orf2, and is the approved symbol as determined by the HUGO Gene Nomenclature Committee (HGNC). The minimal region of amplification was determined using SMRT aCGH and SeeGH filtered raw data ( Figure 3 ). Three of these five cases (285, 286, and 303) also included PROSC as part of the amplicon; the FISH probe encompassed all three genes due to their proximity. The average amplification ratios for the BACs representing the four different regions of 8p, as determined by FISH, are shown in Figure 2c . The amplification ratios relative to centromere copy number, for the novel amplicon range from 3.8 to 5.9, compared to FGFR1 amplification ratios that range from no amplification (ratio 1.1) to a ratio of 4.0.
The novel amplicon is present in 24% of clinical breast cancer cases and shows a positive correlation with poor survival
To clarify the prevalence of this amplicon in breast cancer, the same 438 case TMA was hybridized with a The novel amplicon shows a positive correlation with poor survival using the Kaplan-Meier method and a cutoff amplification ratio of 1.5 (P ¼ 0.0101) (Figure 4a and b). Significance of the novel amplicon was maintained in multivariate analysis (P ¼ 0.0007) (Figure 4c ). In contrast, FGFR1 does not show a significant correlation with patient survival (P ¼ 0.0953). Amplification of neither the novel amplicon nor FGFR1 showed correlation with any of the biomarkers -ER, p53, Ki67, C-MYC, Cyclin-D1, HRG, HER1, HER2, and HER3 -or with the clinicopathological markers -tumor grade, nodal status, or histological subtype, after a Bonferroni adjustment for multiple comparisons. There is, however, a highly significant correlation between the novel amplicon and FGFR1 (Po0.001), and both the novel amplicon and FGFR1 show significant correlation with NRG1 aberrations (Po0.001, P ¼ 0.002, respectively). NRG1 aberrations do not correlate with amplification events in other chromosomal regions: C-MYC (P ¼ 0.241) and CCND1 (P ¼ 0.140) ( Table 1) .
SPFH2 most significantly correlates overexpression with amplification as determined by real-time PCR A second, independent breast cancer array was prepared from 40 cases, each with paired RNA samples isolated from snap frozen malignant and surrounding benign breast tissue. The array was hybridized with a Vertical red left line represents a log 2 ratio between the sample and reference channels of À0.5, vertical purple middle line represents a log 2 ratio of 0, and the vertical green right line represents a log 2 ratio of þ 0.5. Each individual black spot represents one BAC clone and shows the amplification ratio as compared to normal DNA with ratios to left and right of the purple line representing losses and gains, respectively. There is consistent amplification of the novel amplicon in all five samples. (c) A graphical representation of amplification ratios obtained from FISH for all BACs located on the left side of the schematic, grouped according to color. Graph bars from left to right; 5 0 NRG1 (blue), 3 0 NRG1 (tan), novel amplicon (purple), and FGFR1 (burgundy). Only the novel amplicon consistently shows increased copy number in these five cases 8p abnormalities in clinical breast cancer LM Prentice et al combination of three probes derived from the new 8p amplicon, FGFR1, and centromere 8. Using this array, 29 cases had interpretable FISH results and nine of these had the novel amplicon. Real-time PCR was used to determine gene expression levels for FLJ14299, SPFH2, PROSC, and FGFR1 in order to correlate expression with amplification. Using a twofold cutoff value as indicative of overexpression, four cases were found to overexpress SPFH2 and overexpression correlated significantly with gene amplification as determined by Fisher's exact test (P ¼ 0.005) ( Table 2 ). These four cases had the highest amplification ratios (8.4, 2.4, 2.1, 1.9). Six cases showed overexpression of FLJ14299, with a borderline significant correlation with gene amplification (P ¼ 0.056). Of these six cases, two did not exhibit gene amplification. PROSC overexpression occurred in five cases and showed no significant correlation with amplification (P ¼ 0.287). Two of these five cases did not show gene amplification. FGFR1 was overexpressed in nine cases, with a significant correlation with gene amplification (P ¼ 0.022), but more than half of these cases (5/9) did not have gene amplification. Multivariate analysis results using Cox's regression in a backwards stepwise elimination using the following variables: HER2, Grade, ER status, lymph node status, and the novel amplicon. Only the novel amplicon and lymph node status are of independent prognostic significance. Asterisk indicates significant P-value
Discussion
We report the presence of NRG1 gene rearrangements in 4.7% of breast cancers. Our findings are similar to those of Huang et al. (2004) , who found 6% of breast cancer cases with NRG1 gene rearrangements. These are the first two reports of NRG1 gene aberrations in clinical tumor samples, although these rearrangements have been previously characterized in breast cancer cell lines . Unlike the current study, Huang et al. do not report any cases of amplification with their NRG1 probes, only loss. Neither Huang et al. nor our study shows correlation of NRG1 gene aberrations with the expression of HRG, the HRG receptors (HER1, HER2, HER3, or HER4), or with any specific molecularly or clinically defined subtype of breast cancer. These findings suggest that NRG1 rearrangements are not part of a gene-specific oncogenic translocation event. Although NRG1 translocations in clinical breast cancers could have a role in breast cancer development, a more likely scenario is that these breakpoints result in break-fusion-bridge (BFB) cycles that create amplified regions centromeric to the NRG1 breakpoint, leading to overexpression of novel oncogenes, a possibility suggested by Birnbaum et al. (2003) . This hypothesis is supported by the discovery of the novel amplified region centromeric to NRG1 and its correlation with poor patient survival. This region is amplified in 24% of breast cancer cases and is prognostically significant. FISH data from three breast cancer cell lines (T-47D, MDA-MB-361, ZR-75-1) demonstrated that translocations involving 8p12 are accompanied not only by amplification of various genes within the region but also by additional rearrangements such as deletion, duplication, and inversion (CourtayCahen et al., 2000) . These breakpoints and those found by Adelaide et al. (2003) could be the initiating events that lead to the BFB mechanism for gene amplification as has been suggested for Her2 and Topo2A (Jacobson et al., 2004) . The BFB cycle is characterized by breakpoints surrounding the amplicon and loss of genes telomeric to the amplified region (Coquelle et al., 1997) . Consistent with the BFB model, the loss of the 5 0 -end of the NRG1 gene, which is telomeric to the site of amplification, is seen much more frequently than loss of the 3 0 -end of NRG1 (11 cases versus one case). In order for the BFB cycle to lead to successful amplification, a second breakpoint region centromeric to the amplicon is required ( Figure 5 ). There have been several reports of entire 8p arm loss in breast cancer cell lines 
*Indicates statistical significance Figure 5 Schematic representation of the BFB mechanism. Initiation of the BFB cycle by a double-stranded break of sister chromatids after S-phase replication. The breakpoint within the NRG1 gene is represented by a broken line. Broken ends become fused and form a chromosomal bridge during mitosis with spindle attachment to the centromeres. The bridged chromosome breaks during anaphase leaving duplicate copies of the novel amplicon and FGFR1 on the same chromosome. Cycle repeats with a second breakpoint that creates specific amplification of the novel amplicon as compared to FGFR1 or NRG1
and this may reflect a second breakpoint region centromeric to the amplified region (Rummukainen et al., 2001) . Two breakpoint regions centromeric to the novel amplicon, with one located telomeric to FGFR1, would explain the difference in amplification frequencies between the novel amplicon (24%) and FGFR1 (15%).
In a region such as 8p11-12, the BFB-based mechanism through which multiple amplicons can develop is likely very complex and requires multiple discrete breakpoints. The underlying genetic defects that permit the development of multiple amplicons within breast cancer genomes are not yet characterized.
The novel 8p12-derived amplicon described herein contains two genes, FLJ14299 and SPFH2. When the expression levels of these genes, as assessed by quantitative real-time PCR, are compared with gene copy number, SPFH2 expression most significantly correlates with gene amplification. Although the function of the translated product of SPFH2 has yet to be elucidated, its gene product has been isolated from caveolae and lipid raft-enriched fractions of the human endothelial membrane (Sprenger et al., 2004) . By dissociating lipid rafts and HER2 clusters, Nagy et al. (2002) demonstrated that HER2 association with HER3 decreased, as was EGF-and HRG-induced tyrosine phosphorylation of Shc. The location of SPFH2 within a clinically significant amplicon in breast cancers, the association between amplification and overexpression, and its presence in lipid rafts all suggest an oncogenic role for SPFH2 in breast cancer. FLJ14299 amplification has been described in the cell lines SUM-44 and SUM-225 and is associated with overexpression at the mRNA level (Ray et al., 2004) . FLJ14299 gene contains the C 2 H 2 zinc-finger domain present in several other tumor-related genes such as BCL6 (lymphoma), ZNF217 (breast carcinoma), and GLI (sarcoma), and could indicate a DNA-binding region (Ray et al., 2004) . Our study shows that FLJ14299 is the most frequently overexpressed of the three genes and shows a borderline significant correlation with amplification. As PROSC was part of the amplicon in only three of five BAC array CGH cases and does not show correlation between amplification and overexpression in the smaller series, it is likely not an oncogenically important element in the amplicon.
The adjacent FGFR1 gene has been shown to be amplified in 9-15% of breast cancers, which is consistent with our findings (15%), and has been implicated as the driver gene for the 8p11-12 amplicon (Ugolini et al., 1999) . Similar to our study, Huang et al. (2004) found a significant association of FGFR1 expression with NRG1 aberrations. FGFR, like other single transmembrane growth factor receptors, transduces signals across the cell membrane after binding extracellular ligands (Powers et al., 2000) . However, although high FGFR1 oncogene amplification was demonstrated in three breast cancer cell lines SUM-44, SUM-52, and SUM-225, FGFR inhibition failed to slow growth, suggesting that other genes may be responsible for this amplicon and/or breast cancer progression (Ray et al., 2004) .
FGFR1 was also found to be coamplified with CCND1 (11q13) in the breast cancer cell line MDA-MB-134 and 12 of 225 breast cancer specimens (Bautista and Theillet, 1998) . FGFR1 and CCND1 gene coamplification was associated with a worse prognosis in a cohort of 640 breast cancer cases (Cuny et al., 2000) . A link between FGFR and D cyclins has been found within the G1 phase of the cell cycle. When FGFR activity is inhibited, cyclins D1 and D2 are downregulated resulting in cell cycle arrest at G1 mediated by the RB phosphorylation pathway (Koziczak et al., 2004) . Chromosome 11q was assessed by BAC array CGH in our five select cases to determine if coamplification events existed. Besides a minor amplification at 11q14.1 (results not shown), which did not include the genes DOC4 and CCND1 or other regions previously implicated in NRG1 translocations (Bautista and Theillet, 1998; Adelaide et al., 2000) , our study did not find any coamplification events in the five select cases analysed. Our study also showed no correlation between FGFR1 and CCND1 amplifications as determined by FISH. While FGFR1 amplification may prove to be significant in breast cancer, it appears to be distinct from the novel amplicon. Compared to the novel amplicon, FGFR1 is less commonly amplified as determined by array CGH and FISH, and it is not a significant prognostic indicator.
Our study has demonstrated a novel amplification event located within the 8p11-12 region that is significantly associated with poor survival and maintains significance as an independent prognostic indicator in multivariate analysis. This novel amplicon also correlates with NRG1 aberrations supporting a hypothesis that breakpoints within the NRG1 gene lead to BFB cycles that result in amplification of a novel oncogene. SPFH2 is a potential candidate for this oncogene.
Materials and methods
Breast cancer case series and TMA construction
The initial, larger TMA was constructed using formalin-fixed, paraffin-embedded tissue blocks received from the Department of Pathology at Vancouver General Hospital during the period 1974-1995. Case selection and TMA construction have been described previously (Parker et al., 2002; Makretsov et al., 2003 Makretsov et al., , 2004b . Breast tumor samples used for the second, smaller TMA were obtained from women undergoing lumpectomy or mastectomy for breast cancer in Victoria, British Columbia (Royal Jubilee Hospital and Victoria General Hospital), in collaboration with the Department of General Surgery and the Department of Anatomic Pathology from June 1998 to June 2000. Briefly, representative areas of carcinoma were selected and marked on the hematoxylin and eosin slides and corresponding tissue blocks for TMA construction. The TMAs were assembled using a tissuearraying instrument (Beecher Instruments, Silver Springs, MD, USA), with two 0.6 mm cores per case. Outcome data were available for all 495 patients on the larger TMA, with median follow-up of 15.4 years (range 6.3-26.6 years). For statistical analysis, only 438 cases with invasive breast carcinoma and known tumor grade are analysed. Ethical approval was obtained to perform this study from the Clinical Research Ethics Board of the University of British Columbia.
RNA isolation
Total cellular RNA was extracted from samples by the acid-phenol guanidium method (Chomczynski and Sacchi, 1987) with TRIzol as recommended by the manufacturer (www.lifetech.com). After isolation, the RNA was treated with 1 U DNAse (RQ1, Promega, Wisconsin, USA) in the buffer supplied to remove contaminating DNA. The quality of RNA was assessed by confirming the presence of intact 18 and 26s ribosomal RNA bands by agarose gel electrophoresis.
Fluorescent in situ hybridization
Sections (6 mm thick) of the TMA slides were pretreated for FISH as described elsewhere (Makretsov et al., 2004a) . Locusspecific FISH analysis for all genes, including both ends of NRG1, FGFR1, and the novel amplicon, was performed using the following BACs from the Human BAC Library RPCI-11 (BACPAC Resources Centre, Children's Hospital Oakland Research Institute) (listed telomeric to centromeric): 566H8, 10L15, 97N12, 478B14, 15H14, 1002K11, 11N9, 692P18, 451O18 (for the NRG1 gene), 863K10 (novel amplicon), 350N15, and 675F6 (FGFR1). BACs 566H8, 10L15, 350N15, 675F6, 97N12, and 478B14 were directly labeled with Spectrum Green and BACs 11N9, 692P18, 451O18, 863K10, 1002K11, and 15H14 were directly labeled with Spectrum Orange. The chromosomal locations of all BACs were validated using normal metaphases (results not shown). The well-characterized breast cancer cell line MDA-MB-175 was also used to verify the flanking NRG1 probes and after multicolor karyotyping (MFISH) treatment showed t(8;11). The aqua-labeled a-satellite control DNA probe for chromosome 8 (CEP8) was purchased from Vysis (Downers Grove, IL, USA). Probe labeling and FISH was performed using Vysis reagents according to the manufacturer's protocols (Vysis, IL, USA). Slides were counterstained with 4,6-diamidino 2-phenylindole for microscopy. For each of the TMA slides, FISH signals and patterns were identified on a Zeiss Axioplan epifluorescent microscope and were scored either manually (oil immersion Â 100) or using Metasystems Metafer software (MetaSystems Group Inc., Belmont, MA, USA) and enumerated in approximately 40 morphologically intact and nonoverlapping nuclei. MFISH of the cell line MDA-MB-175 was performed as published in detail elsewhere (Khoury et al., 2003) . Amplification was defined as a copy number to control copy number ratio of 1.5 or greater; loss was consider as a ratio of 0.6 or less.
Immunohistochemical analysis of HRG, HER3, and HER4
Immunohistochemical analysis was performed on 4-mm-thick sections from the TMA after heat-induced epitope retrieval. Primary antibodies were applied as follows: HRG (clone 7D5, diluted 1 : 10), HER3 (rabbit polyclonal, diluted 1 : 400), and HER4 (clone HFR-1, diluted 1 : 160), all purchased from NeoMarkers, Lab Vision (Freemont, CA, USA). HRG immunoreactivity was scored according to the percentage of cells positive for the cytoplasmic reaction as follows: negative o10%, weak 10-40%, and strong >40% of cells stained. HER3 and HER4 were scored as negative or positive (Wiseman et al., 2005) . Linkage of the genetic data and HRG staining with tumor size, nodal status, the immunohistochemical biomarkers ER, PR, p53, Ki67, HER1, HER2, and clinical outcome data was performed as described previously (Liu et al., 2002) .
BAC array CGH
A subset of five cases representing all types of NRG1 gene rearrangements, that is, case 77 (type A), cases 179 and 286 (type B), and cases 303 and 285 (type C) were analysed by BAC array CGH to both verify the FISH results and provide high-resolution mapping (B0.1 Mb) of the 8p11-12 region. We performed array CGH on microarrays containing 32 433 BAC-derived amplified fragment pools spotted in triplicate (97 299 elements) over two 18 mm Â 54 mm arrays, as described previously .
BAC array CGH imaging and analysis
Cyanine-3 and cyanine-5 images (16 bit) were acquired using a CCD camera system (Applied Precision, Issaquah, WA, USA). Images were then analysed using SoftWoRx Tracker Spot Analysis software (Applied Precision). Genomic imbalances and their associated breakpoints were identified using genetic local search algorithms within the software package aCGHsmooth developed by Jong et al. as described previously (Jong et al., 2003; de Leeuw et al., 2004) . Custom software (SeeGH) was used to visualize all data and is available upon request, as published elsewhere Watson et al., 2004) .
Quantitative RT-PCR
The probe sequences used for SPFH2 and FLJ14299 were CCAGAGGCAATCCG and AGACTAGCTTCAGCCTC, respectively. The forward and reverse primer sequences for SPFH2 are CGGGTAACAAAGCCCAACAT, TCACTTTC CATCAACTCGTAGTTTCT, while the forward and reverse primer sequences for FLJ14299 are GCCATACGCGCTG TATGGA, GAGGAAGAGCTGTAGTTACTGGTATCC. PROSC and FGFR1 probes with primers included were obtained as a 20x target assay from Applied Biosystems (Foster, CA, USA). All probes were used at 100 nM and all primers at 900 nM concentrations. Cycling was set at 951C for 10 min, then 40 cycles of 951C (15 s)/601C (1 min). Results were assessed using ABI software and normalized to Stratagene's Universal Human Reference RNA mix consisting of 10 different human cell lines (La Jolla, CA, USA). Overexpression was defined as a 2.0-fold or greater level of mRNA as compared to control.
Statistical analysis
Statistical analysis was performed using SAS software version 8.02. The optimal amplification ratio cutoff value generated by X-tile (Camp et al., 2004 ) was 1.38. A cutoff value of 1.5 was used for all analysis for more stringent results. The prognostic significance of the novel amplicon, amplified FGFR1, and NRG1 aberrations was assessed using Kaplan-Meier survival estimates and the log-rank test. Fisher's exact test was used to test for associations between the novel amplicon, amplified FGFR1, and NRG1 aberrations. After a Bonferonni adjustment for multiple comparisons was made, associations were deemed to be statistically significant if the adjusted P-value was less than 0.05/14 ¼ 0.00357. Multivariate analysis of the prognostic significance of the novel amplicon was performed using Cox's proportional hazards model and a backwards stepwise method to remove variables from the model. Multivariate analysis was performed with a model that included the novel amplicon, lymph node status, HER2, Grade, and ER as variables. Fisher's exact test was used to test for correlations between amplification and overexpression. 
